Sanwa Kagaku Kenkyusho Co., Ltd.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
    • Generic Drugs
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Distributors
See more in Biomedtracker

Latest on Sanwa Kagaku Kenkyusho Co., Ltd.

Scrip

Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities

 
• By Lisa Takagi, Jung Won Shin, Dexter Jie Yan, and Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Ono Calls On PRISM For Oncology Di

Scrip

Finance Watch: Fundraising Shows Preference For Later-Stage Companies

 
• By Mandy Jackson

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr

Scrip

Asia Deal Watch: Eisai Advances Portfolio Focus With Divestiture Of Two Products To DKSH

 
• By Lisa Takagi, Jung Won Shin, Dexter Jie Yan, and Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Eisai Divests Asian Rights For Two

Scrip

Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma

 
• By Vibha Ravi, Anju Ghangurde, Joseph Haas, and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Huadong Pays $20m Up Front For ADCs Fro